Laura Moro
Novara, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Editorial Expression of Concern: Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.
Journal: Oncogenesis
Published: June 18, 2026
Corrigendum to "Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells" [Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 1832(12) (2013) 2085-2096].
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: March 11, 2026
Defined pulsed electro-magnetic field exposure suppresses stemness and potentiates temozolomide-induced apoptosis in glioblastoma cells.
Journal: Scientific reports
Published: November 26, 2025
An analysis of succinate dehydrogenase B in pleural mesothelioma.
Journal: Discover oncology
Published: September 25, 2025
EZH2 Inhibition in Mesothelioma Cells Increases the Release of Extracellular Vesicles That Skew Neutrophils Toward a Protumor Phenotype.
Journal: International journal of molecular sciences
Published: September 04, 2025
A Selective ALDH1A3 Inhibitor Impairs Mesothelioma 3-D Multicellular Spheroid Growth and Neutrophil Recruitment.
Journal: International journal of molecular sciences
Published: March 16, 2023
Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma.
Journal: Cancers
Published: February 01, 2023
Corrigendum: CDKN2A determines mesothelioma cell fate to EZH2 inhibition.
Journal: Frontiers in oncology
Published: October 27, 2022
The Strange Case: The Unsymmetric Cisplatin-Based Pt(IV) Prodrug [Pt(CH3COO)Cl2(NH3)2(OH)] Exhibits Higher Cytotoxic Activity with respect to Its Symmetric Congeners due to Carrier-Mediated Cellular Uptake.
Journal: Bioinorganic chemistry and applications
Published: October 25, 2022
Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines.
Journal: Molecules (Basel, Switzerland)
Published: June 29, 2021
Last Updated: 09/26/2026